anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

191,701-191,760 of 319,975

filter-aware
04
The slide uses a combination of headshots for the team and a metric-based footer to establish credibility.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · Team1 hit
05
The slide uses a hierarchical structure to connect a high-level objective to three distinct operational pillars.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · Solution1 hit
06
The slide uses a Gantt-style visualization to represent clinical trial progress for multiple drug candidates.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
07
The slide uses a hub-and-spoke diagram to represent the platform model.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
08
The slide uses a split-view layout: a list of past achievements on the left and a timeline of future events on the right.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Why Now1 hit
09
ATAI | Investor Presentation Deck | 36 slidesATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Why Now1 hit
10
ATAI | Investor Presentation Deck | 36 slidesATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
11
The slide uses a split layout: left side defines the condition and market size, right side outlines the 'Urgent Need for Innovation' using a process-like list of pain points.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
Includes clinical trial data visualization and product summary table.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
13
The slide uses a dark sidebar for product specs and a white main area for clinical data visualization.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
14
The slide uses a split-layout with a dark sidebar for key facts and a white main area for clinical data visualization.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
15
Includes chemical structure diagrams and multiple bar charts showing dose-response relationships.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
16
The chart uses a dot plot to show individual patient CADSS scores over time across three cohorts (30mg, 60mg, Placebo).ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
17
The slide uses a timeline diagram to illustrate the clinical trial flow and two boxes to detail study design and operational status.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
18
The slide uses a matrix-style comparison table to highlight competitive advantages.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
19
ATAI | Investor Presentation Deck | 36 slidesATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
20
The slide uses a split-layout: left side defines the condition and global burden, right side details the 'huge need for development' using a vertical timeline-like list.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
21
The slide uses a vertical timeline/process flow to show the progression of clinical development alongside key de-risking milestones.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
22
Includes a quote from Keith Nuechterlein and a detailed clinical trial timeline.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
23
The slide highlights efficacy in cognitive endpoints for a specific patient population (DPNP).ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
24
CIAS likely refers to Cognitive Impairment Associated with Schizophrenia.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
25
The slide uses a checkmark system to highlight specific advantages of RL-007 and a few competitors.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
26
ATAI | Investor Presentation Deck | 36 slidesATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
27
The slide uses a split-layout: left side provides market context and statistics, right side outlines the 'unaddressed need' framework.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · Market Sizing1 hit
28
Includes a sidebar summary and a clinical trial design overview.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
29
The slide uses a checkmark matrix to highlight the competitive advantage of the company's drug candidate.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
30
ATAI | Investor Presentation Deck | 36 slidesATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
31
Uses a combination of a map, metric callouts, and a vertical process-style list to convey urgency.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
32
Includes a summary table on the left and clinical trial data/roadmap on the right.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
33
The table highlights DMX-1002's unique profile compared to withdrawal support and maintenance therapies.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
34
ATAI | Investor Presentation Deck | 36 slidesATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
35
The slide uses a card-based layout to detail the value proposition and operational structure of four distinct entities.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
36
The slide uses a personal narrative to establish the 'why' behind the company's mission.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
01
Slide 1
Corporate mission statement slide.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
02
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
03
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Situation & Context1 hit
04
Includes a specific date reference at the bottom: October 25, 2022.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Situation & Context1 hit
05
Uses a two-column layout to contrast 'Significant Burden' with 'Urgent Need for Innovation'.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a Gantt-style visualization to represent clinical trial progress for various drug candidates.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · AgitationLoop · Cost Of Inaction1 hit
07
The slide uses a horizontal arrow timeline to organize clinical trial phases and results.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · AgitationLoop · Cost Of Inaction1 hit
08
Slide 08 in a presentation deck.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution1 hit
09
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution1 hit
10
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses chemical structure diagrams to illustrate the relationship between the racemate and its enantiomers.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
Data source: Zanos et al., 2016. The charts show dose-dependent reduction in immobility time.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide uses a third-party study (Yang et al., 2015) to support the claim of a superior therapeutic index for R-ketamine.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
The slide contrasts the therapeutic benefit (MADRS) with the lack of side effects (CADSS) compared to S-Ketamine benchmarks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
CADSS = Clinician administered dissociative states scale. Data points are clustered by time interval.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
The slide uses a standard clinical trial flow diagram (randomization to treatment arms).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The slide uses a comparison structure to contrast safety/tolerability goals against efficacy goals.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
19
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
20
The chart compares 25mg, 10mg, and 1mg (comparator) dosages. Statistical significance is marked with asterisks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide outlines the study arms, randomization ratios, and primary endpoint timing for two distinct clinical trials.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The slide uses a list of three key regulatory takeaways followed by a forward-looking implication for the pipeline.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
The slide introduces the drug candidate VLS-01, providing its chemical identity and current clinical trial status.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
25
The chart displays statistical significance markers (p-values) at Day 1, Day 2, and Day 7.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
26
The slide uses a process flow diagram to represent clinical trial cohorts and SMG (Safety Monitoring Group) review gates.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
27
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit